ABCG2 and chronic myelogenous leukemia, BCR-ABL1 positive: Recent studies by Nouri et al. [57] and Mohammadi et al. [58] also concluded that the ABCG2 C421A SNP had no impact on imatinib response in Iranian CML patients.